Literature DB >> 14521942

Role of class I and class II histone deacetylases in carcinoma cells using siRNA.

Keith B Glaser1, Junling Li, Michael J Staver, Ru-Qi Wei, Daniel H Albert, Steven K Davidsen.   

Abstract

The role of the individual histone deacetylases (HDACs) in the regulation of cancer cell proliferation was investigated using siRNA-mediated protein knockdown. The siRNA for HDAC3 and HDAC1 demonstrated significant morphological changes in HeLa S3 consistent with those observed with HDAC inhibitors. SiRNA for HDAC 4 or 7 produced no morphological changes in HeLa S3 cells. HDAC1 and 3 siRNA produced a concentration-dependent inhibition of HeLa cell proliferation; whereas, HDAC4 and 7 siRNA showed no effect. HDAC3 siRNA caused histone hyperacetylation and increased the percent of apoptotic cells. These results demonstrate that the Class I HDACs such as HDACs 1 and 3 are important in the regulation of proliferation and survival in cancer cells. These results and the positive preclinical results with non-specific inhibitors of the HDAC enzymes provide further support for the development of Class I selective HDAC inhibitors as cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14521942     DOI: 10.1016/j.bbrc.2003.09.043

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  74 in total

Review 1.  Role of protein tyrosine phosphatases in cancer.

Authors:  Tasneem Motiwala; Samson T Jacob
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

2.  Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.

Authors:  Jennifer Jurkin; Gordin Zupkovitz; Sabine Lagger; Reinhard Grausenburger; Astrid Hagelkruys; Lukas Kenner; Christian Seiser
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

Review 3.  Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Authors:  Hongmei Li; Chris E Nelson; Brian C Evans; Craig L Duvall
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

4.  Design and Validation of FRESH, a Drug Discovery Paradigm Resting on Robust Chemical Synthesis.

Authors:  Qi Shi; Thomas M Kaiser; Zackery W Dentmon; Mariangela Ceruso; Daniela Vullo; Claudiu T Supuran; James P Snyder
Journal:  ACS Med Chem Lett       Date:  2015-04-03       Impact factor: 4.345

Review 5.  Cellular analysis of the action of epigenetic drugs and probes.

Authors:  Mirjam Hau; Fides Zenk; A Ganesan; Nicola Iovino; Manfred Jung
Journal:  Epigenetics       Date:  2017-01-10       Impact factor: 4.528

6.  Specific activity of class II histone deacetylases in human breast cancer cells.

Authors:  Vanessa Duong; Caroline Bret; Lucia Altucci; Antonello Mai; Céline Duraffourd; Julie Loubersac; Pierre-Olivier Harmand; Sandrine Bonnet; Sergio Valente; Thierry Maudelonde; Vincent Cavailles; Nathalie Boulle
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

7.  Class I HDAC activity is required for renal protection and regeneration after acute kidney injury.

Authors:  Jinhua Tang; Yanli Yan; Ting C Zhao; Rujun Gong; George Bayliss; Haidong Yan; Shougang Zhuang
Journal:  Am J Physiol Renal Physiol       Date:  2014-05-07

8.  Role for histone deacetylase 1 in human tumor cell proliferation.

Authors:  Silvia Senese; Katrin Zaragoza; Simone Minardi; Ivan Muradore; Simona Ronzoni; Alfonso Passafaro; Loris Bernard; Giulio F Draetta; Myriam Alcalay; Christian Seiser; Susanna Chiocca
Journal:  Mol Cell Biol       Date:  2007-04-30       Impact factor: 4.272

9.  Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.

Authors:  Zhenhua Lin; Martina Bazzaro; Mei-Cheng Wang; Kwun C Chan; Shiwen Peng; Richard B S Roden
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

10.  A functional and regulatory network associated with PIP expression in human breast cancer.

Authors:  Marie-Anne Debily; Sandrine El Marhomy; Virginie Boulanger; Eric Eveno; Régine Mariage-Samson; Alessandra Camarca; Charles Auffray; Dominique Piatier-Tonneau; Sandrine Imbeaud
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.